Trethera’s lead candidate, TRE-515, is a first-in-class dCK inhibitor. For the uninitiated, dCK (deoxycytidine kinase) is the rate-limiting enzyme in the nucleoside salvage pathway. By inhibiting this pathway, TRE-515 essentially attempts to starve cancer cells of the building blocks they need to replicate, while simultaneously altering the tumor microenvironment. It’s a bold move: disrupting DNA repair mechanisms is a double-edged sword, but the potential for 'one pill' efficacy in autoimmune and neuroinflammatory diseases suggests a broad mechanism of action that goes beyond oncology.

With only 9 employees and under $1M in revenue, Trethera operates with the agility of a biotech seed stage, yet the focus of a mature pharma player. The lack of disclosed funding rounds is telling—they are likely bootstrapped or backed by a small, concentrated group of true believers. Their traffic profile is peculiar: 42% direct traffic on a site with only 1.8k monthly visits suggests a highly targeted audience. Investors and industry insiders aren't finding them via SEO; they are typing the URL directly because they already know who Trethera is.